| Title: | Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C |
| Authors: | Kawagishi, Naoki Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Kimura, Megumi Browse this author |
| Maehara, Osamu Browse this author |
| Yamada, Ren Browse this author |
| Tokuchi, Yoshimasa Browse this author |
| Kubo, Akinori Browse this author |
| Kitagataya, Takashi Browse this author |
| Shigesawa, Taku Browse this author |
| Suzuki, Kazuharu Browse this author |
| Ohara, Masatsugu Browse this author |
| Nakai, Masato Browse this author |
| Sho, Takuya Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Morikawa, Kenichi Browse this author |
| Ogawa, Koji Browse this author |
| Kudo, Yusuke Browse this author |
| Nishida, Mutsumi Browse this author |
| Sakamoto, Naoya Browse this author |
| Issue Date: | 28-Apr-2021 |
| Publisher: | Nature Research |
| Journal Title: | Scientific reports |
| Volume: | 11 |
| Issue: | 1 |
| Start Page: | 9207 |
| Publisher DOI: | 10.1038/s41598-021-88632-7 |
| Abstract: | We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82232 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
